Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

laropiprant

Known as: (-)-((3R)-4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl)acetic Acid 
A prostaglandin D2 receptor (DP1) antagonist with niacin-induced vasodilation inhibiting activity. Laropiprant binds to and inhibits the activity of… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
In 2016, the American College of Cardiology published the first expert consensus decision pathway (ECDP) on the role of non… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 2
  • figure 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2014
2014
  • D. Lloyd-Jones
  • The New England journal of medicine
  • 2014
  • Corpus ID: 4973671
For the past four decades, the concentration of cholesterol contained in high-density lipoprotein (HDL) particles has been a… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Aims Niacin has potentially favourable effects on lipids, but its effect on cardiovascular outcomes is uncertain. HPS2-THRIVE is… Expand
Is this relevant?
Review
2009
Review
2009
Aims: To summarise the metabolic responses to niacin that can lead to flushing and to critically evaluate flushing mitigation… Expand
Is this relevant?
2009
2009
BACKGROUND Prostaglandin D(2) is a proinflammatory mediator believed to be important in asthma and allergic rhinitis (AR… Expand
  • figure 1
  • figure 2
  • table I
  • table II
  • table III
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Niacin has beneficial effects on a patient's lipid and lipoprotein profiles and cardiovascular risk, particularly at doses >2 g… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Niacin (nicotinic acid) is not optimally used mainly because of flushing, a process mediated primarily by prostaglandin D(2… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Background:  Improving lipids beyond low‐density lipoprotein cholesterol (LDL‐C) lowering with statin monotherapy may further… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Niacin (nicotinic acid) reduces cardiovascular events in patients with dyslipidemia. However, symptoms associated with niacin… Expand
Is this relevant?